Zhuzhou Yuancheng Tec Ltd

Name: Iressa / Gefitinib Tablets

Alias: GEFITINIB; AKOS 91371; N- (3-Chloro-4-fluoro-phenyl) -7- 4-fluorophenyl) -7-methoxy-6- [3- (4-morpholinyl) propoxy] -4-quinazolinamine; ZD 1839; - [3- (4-morpholinyl) propoxy] -; Gefitinib (TINIBS); Gefitinib, Iressa, ZD1839; Gefitinib Base

CAS number: 184475-35-2

Molecular formula: C22H24ClFN4O3

Molecular weight: 446.9024

Indications

This product is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Previous chemotherapy mainly refers to platinum and docetaxel treatment.

The efficacy of this product in patients with locally advanced or metastatic non-small cell lung cancer who have previously received chemotherapy is based on the survival benefit of a pre-set Asian subgroup based on large-scale placebo-controlled clinical trials (Note: The overall population in this trial did not show improvement Disease-related symptoms and prolongation of survival) and survival data from non-controlled clinical trials in China.

Two large randomized controlled clinical trials showed that first-line treatment of locally advanced or metastatic NSCLC with gefitinib plus platinum-containing chemotherapy did not show clinical benefit, so such a combination is not recommended